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http://www.malariajournal.com/content/13/1/491RESEARCH Open Access“Every drug goes to treat its own disease…” – a
qualitative study of perceptions and experiences
of taking anti-retrovirals concomitantly with
anti-malarials among those affected by HIV and
malaria in Tanzania
Peter E Mangesho1*, Joanna Reynolds2, Martha Lemnge3, Lasse S Vestergaard4 and Clare IR Chandler5Abstract
Background: Little is known about how people living with human immunodeficiency virus (HIV) experience
malaria and the concomitant use of anti-malarial treatments with anti-retrovirals (ARVs). An understanding of how
patients make sense of these experiences is important to consider in planning and supporting the clinical management
and treatment for co-infected individuals.
Methods: A qualitative study was conducted in Tanzania alongside a clinical trial of concomitant treatment for HIV and
malaria co-infection. Focus group discussions were held with people receiving treatment for HIV and/or malaria, and
in-depth interviews with health workers responsible for HIV care and members of the clinical trial team. Data were
analysed inductively to identify themes and develop theoretical narratives.
Results: Results suggest that people living with HIV perceived malaria to be more harmful to them due to their
compromised immune status but saw the disease as unavoidable. For those enrolled in the clinical controlled study,
taking anti-malarials together with ARVs was largely seen as unproblematic, with health workers’ advice and endorsement
of concomitant drug taking influential in reported adherence. However, perceptions of drug strength appeared to compel
some people not enrolled in the clinical study to take the drugs at separate times to avoid anticipated harm to the body.
Conclusions: Management of HIV and malaria concurrently often requires individuals to cross the domains of different
disease programmes. In the context of a trial concerned with both diseases, patients experienced the support of clinicians
in guiding and reassuring them about when and how to take drugs concomitantly. This points towards the need to
continue to strive for integrated care for patients with HIV.
Keywords: HIV, Malaria, Concomitant conditions, Tanzania, Qualitative researchBackground
The global burdens of malaria and human immunodeficiency
virus (HIV) are high, together causing over 2.5 million
deaths in 2009 [1,2]. In many sub-Saharan African
countries, including Tanzania, populations are at risk
of HIV and malaria concurrently. However, action to
tackle the two diseases is often carried out in parallel.* Correspondence: pmangesho@nimr.or.tz
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unless otherwise stated.The need for coordinated and integrated approaches
is recognized as essential, and a focus has been
placed on health systems as a whole in supporting
programmes for different diseases [3,4]. The negative
clinical consequences of HIV-malaria co-infection are
already well established, including a higher risk of malaria
and developing more severe clinical symptoms amongst
HIV-positive people, as reviewed by C Flateau et al. [5].
Investment in supply of effective anti-malarials and
anti-retrovirals (ARVs) has been significant [6], and there
is also an increasing knowledge about the potentialtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Thus recent studies suggest that drug-drug interac-
tions between certain anti-malarials and anti-retrovials
exist, which affects achieved drug concentrations and
hence may influence the efficacy and/or the safety
profiles of those treatments, depending on the medicine
combination [7-9].
Despite the relationship between the two diseases,
however, the management of treatment for malaria and
HIV co-infection has received comparatively little attention,
and there is a paucity of research around the experiences of
people needing receiving treatment for co-infection, and
how patients manage concurrent medicine taking. Beyond
the clinical implications of treating co-infection of HIV and
malaria, greater understanding of people’s experiences of
taking concomitant treatments is imperative to support the
management of these diseases together. A wide literature
on ‘adherence’ to treatment regimens for various diseases
has highlighted the importance of attending to experiential
accounts of taking medication, to understand the range of
social, physical and material factors which can shape
patients’ treatment-taking and seeking behaviours [10,11].
There are clear clinical implications of patients not seeking
or following treatments as recommended either for malaria
[12] or HIV [13]. In addition, the management of treatment
at the individual level carries implications for broader
public health, specifically in terms of the potential
impact on the development of resistance to malaria or HIV
drugs [14,15]. These issues are likely to be compounded by
patients’ experiences of taking HIV and malaria treatments
concomitantly for co-infection.
The meanings of malaria and of HIV and AIDS to
those affected across the African continent have been
explored extensively, leading to two large, but mostly
separate, bodies of literature [16,17]. These works
have broadly examined how conceptualizations and
experiences of disease, treatment options, and perceptions
of effectiveness and side effects of medication may
influence treatment-seeking and prevention behaviours
for either HIV or malaria alone [18-22]. There is a notable
absence of literature about people’s experiences of
treatment and taking medications concomitantly for
HIV and malaria co-infection. Studies have explored
experiences of concomitant treatment for HIV and other
co-infections, such as tuberculosis (TB) or hepatitis C
[23-25], although this remains largely in the domain of
clinical or pharmacokinetic research [26].
A qualitative study was designed to understand how
people who straddle these two diseases of HIV and
malaria make sense of their situation and especially
the concomitant drugs to be taken. The study drew
on theoretical perspectives from medical anthropol-
ogy, particularly considering the ‘charm’ or ‘power’ of
medicines [27].Methods
Study setting
This research took place at Muheza District Hospital in
northeast Tanzania where malaria is endemic, and
prevalence of HIV is estimated at 6.7% [28]. The hospital
had a separately funded and slightly separated HIV
centre where all HIV positive patients could receive
ongoing care for HIV and other illnesses. Treatment for
malaria for HIV-positive patients is supposed to be free
although medicines were not always available and
patients at times had to buy them from other public or
private facilities. The current nationally recom-
mended first-line treatment for malaria in Tanzania is
artemether-lumefantrine (ALu), and for HIV a selection of
nevirapine- or efavirenz-based combinations.
The qualitative study was conducted in 2011 alongside
a clinical controlled study (trial number NCT00885287,
[29]) which assessed the therapeutic efficacy, clinical
safety and pharmacokinetic interactions of anti-malarials
taken concomitantly with anti-retrovirals in adults
co-infected with HIV and uncomplicated malaria, against
comparator groups of HIV-positive adults co-infected
with malaria but not taking anti-retrovirals, and
HIV-negative adults with malaria between 2009 and 2012.
Participants for the clinical study were recruited among
patients presenting with fever at the HIV centre or general
outpatients section of the hospital, where they were tested
for malaria using rapid diagnostic tests (RDTs). If testing
positive for malaria they were invited to join the clinical
study, received free treatment for malaria and were
monitored with frequent follow-up visits and repeated
malaria testing over 42 days.
Qualitative study design
A qualitative methodology based on an interpretative
(meaning-based) approach [30] was employed to explore
people’s perceptions and experiences of taking medicines
for HIV and malaria. Focus group discussions (FGDs) were
selected to provide an opportunity to explore experiences
and points of reference that are shared and those in dispute
within specified sub-groups, through observing social
interactions in groups [31]. In-depth interviews (IDIs) were
considered appropriate for understanding the perspectives
of individuals and gaining narratives of their experiences
with particular topics [32].
Sample
To explore a range of perspectives on taking HIV and
malaria treatment concomitantly the study sampling
strategy was devised around three sub-groups of ‘patients’
who had received treatment for HIV and/or malaria, and
an additional sub-group of health workers who had
experience of delivering care to HIV patients either within
or beyond the clinical study. The three sub-groups of
Table 1 Number of FGDs and IDIs conducted by sub-group
Group Sub-group
Number
completed
Male Female
FGDs
Treatment
recipients
A (HIV-positive, receiving ARVs,
completed participation in clinical
controlled study of Alu efficacy
and safety
1 3
B (HIV-negative, no ARV, completed
participation in clinical controlled study
of ALu efficacy and safety)
2 2
C (HIV-positive, receiving ARVs, excluded
from participation in clinical study)
1 4
IDIs
Health
workers
Clinical study staff 4
HIV Care and Treatment Clinic health
workers
4
Hospital health workers 2
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people who were HIV-positive and taking ARVs, and who
had recently been diagnosed with malaria and treated with
ALu as part of the clinical study; a comparator sub-group
(B) of HIV-negative people who were diagnosed with
malaria and treated with ALu and had participated in
the comparison arm of the clinical study (group B); and a
second comparator sub-group (C) of HIV-positive people
taking ARVs who had not been eligible to receive ALu as
part of the clinical trial, either because they were not
diagnosed with malaria or had taken other anti-malarials
already (group C). To recruit participants for the
treatment recipient sub-groups A and B, the clinical
study database was used, working backwards in time
from those who had most recently completed the 42-day
follow-up period, to limit the effects of difficulty with
recall over time. Participants for sub-group C were
identified prospectively as part of the ongoing screening
and recruitment for the main clinical study. The health
worker sub-group reflected a purposive and convenience
sample of clinicians and nurses working on the clinical
study, health workers delivering care at the hospital
HIV clinic and other hospital staff from the in- and
out-patients departments.
The planned sample sizes were three to four focus
group discussions per ‘patient’ sub-group, with between
eight and 12 participants in each, and eight to ten individual
in-depth interviews with health workers. These sizes
reflected the intentions of the study to explore a range of
experiences and to be able to make comparisons between
different sets of perspectives, while acknowledging the
scope and resource limitations posed by in-depth qualitative
research methods.
Data collection
FGDs with the three groups of treatment recipients
explored perceptions and experiences of taking ARVs
with anti-malarials as well as other medicines. FGDs
were separated by HIV status and gender to minimize
concerns around disclosure of HIV status and to facilitate
open discussion. IDIs with health workers explored
attitudes and experiences of providing care to patients
co-infected with HIV and malaria. Semi-structured
topic guides were developed and piloted for both the
FGDs and IDIs.
PM facilitated the group discussions and interviews
in Kiswahili, English, or a mixture. With participants’
permission, FGDs and IDIs were audio-recorded and
a note taker was present in the FGDs to record both
verbal and non-verbal communications. FGDs took
place in a room away from the main hospital site, and IDIs
were conducted in a private space on the hospital site. All
recordings were transcribed verbatim in Kiswahili,
translated into English and cross-checked for accuracy.Data analysis
All transcripts were organized and coded by PM and JR
with the assistance of QSR Nvivo 8 qualitative data
management software [33]. The coding process was
informed by principles of grounded theory [34] whereby
analytical categories and concepts were identified by going
through each transcript line-by-line, identifying potential
themes, in an iterative, comparative process. Interpretations
were further developed through discussion among the
research team.
Ethical considerations
The study was approved by the ethical committee of
the London School of Hygiene & Tropical Medicine
(reference A216 5828) and the National Institute for
Medical Research in Tanzania (reference NIMRlHQ/
R.8alVol. IX/1150). The FGDs were segregated by HIV
status, but the nature of the discussions meant that
HIV-positive participants’ status was likely to become
known to other participants during the FGDs. Participants
were made aware of this at the point of invitation to
participate, and reminded at the beginning of the discussion
not to share the content of the discussion beyond the
group. After providing information about the purpose and
procedures of the study, written consent to participation
and being audio-recorded was taken from each participant.
For participants unable to write, a thumb-print was
accepted in place of a signature.
Results
Participants
A total of 13 FGDs were conducted. On average there were
eight to ten participants per discussion with a total of 114
participants (see Table 1). More women participated in the
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greater number of women presenting to the clinic for HIV
treatment. Amongst those with malaria but not HIV, equal
numbers of each gender participated. In total, ten health
worker IDIs were conducted. There were no refusals
to participate. The results presented here focus primarily
on the experiences and perspectives of those participants
living with HIV, and distinctions with the other study
group participants are highlighted where pertinent.
Paradigms of ARVs and anti-malarial medicines
For those living with HIV, general use of medicines was
made sense of in the context of their different experiences
of sickness and treatment which were mediated by
the different programmes or health services on offer.
When taking ARVs and attending the HIV centre
regularly, people had been taught about adherence to
treatment and the need for this was framed in stark
terms. The role of ARVs was perceived as to prolong
life: “You take ARVs so that you live longer, like food,
if you do not eat you die” (Respondent (R) 02; FGD
A2, HIV-positive male). Taking ARVs was described
as a ‘contract’ – ‘mkataba’ – between patients and the
drugs, and therefore implied certain rules around taking
drugs, which had to be adhered to. In particular, the
notion of timing of drug-taking was prominent in
participants’ narratives. Some described choosing their
own schedule whereas others indicated the timing was
directed by a doctor. Adherence to the daily schedule
of taking ARVs was indicated as important for their
effectiveness and to prevent harm:
… you cannot be harmed by the drug if you
concentrate on the schedule of the drug taking (R 03;
FGD C3, HIV-positive female).
The framing of taking ARVs in terms of timing con-
tinue into some accounts of taking ARVs concomitantly
with other drugs, as described in more detail below.
Other medicines, including anti-malarials, were often
spoken about in rather different terms, outside of the HIV
treatment paradigm. Such drugs could be purchased or
obtained easily, with minimal discussion with the vendor
or healthcare provider. Malaria, especially, was considered
a ‘normal’ disease for which a range of possibilities of
treatment were presented. The first-line anti-malarial
drugs, artemether-lumefantrine, were the outcome of a
linear, biomedical process of seeing the doctor, receiving
a diagnosis (including getting tested), prescription of
medicine and getting cured. This mirrored the way
anti-malarials were discussed in the HIV-negative focus
groups. Being tested prior to receiving medicines was
articulated in the FGDs with HIV-positive people as
very important in the fulfilment of this treatmentprocess, for example attending a health facility to be
tested for malaria, if experiencing malarial symptoms.
While some participants mentioned traditional medicine
and miracle healing, most respondents intimated that
these were not as effective as biomedical treatment,
though this could reflect participants’ reluctance to
disclose what might be considered ‘deviant behaviour’
in the context of our study based within the hospital and a
clinical research study. Effectiveness of a treatment was
perceived to be linked to eradication of symptoms or
proof from a medical test that the disease was eradicated.
Making sense of concomitant medicine taking
Given the two different paradigms of medicine taking,
one mediated through the HIV treatment programme of
clearly defined protocols, and the other developed
through long histories of familiarity with malaria as a
disease and easy availability of treatment, HIV patients
had to make sense of concomitant medicine taking by
straddling these two paradigms. Some made sense of this
by extending the ideas developed within HIV treatment
programmes to follow the protocol set out, respecting
biomedical authority, in the form of doctors’ instructions,
over the taking of medicines. However, in the realities of
accessing and taking the drugs, challenges emerged
relating to diagnosis, pill burden and concepts of medicine
strength. Some respondents’ experiential accounts of
how they managed mixing medicines in their daily lives
suggested adaptations to formal protocols may emerge
due to both practicalities and conceptualizations of taking
the drugs together.
Respecting biomedical protocols
Reflecting the discrete approach to HIV and malaria
as enacted through disease control programmes, many
respondents spoke of their drugs as working independently
in the body to address separate health problems:
“every drug one takes goes to treat its own disease in
the body” (R 07; FGD A3; HIV-positive male). Acquiescing
to the authority of biomedicine as experienced through
ARV treatment programmes, many patients followed
the lead of biomedical workers in their responses to
concomitant medicine taking: “If the doctor prescribes
you should take all the medicines together, you have to do
it and that is what I do” (R02; FGD-A4; HIV-positive
female). With this perspective, mixing anti-malarials with
ARVs was conceptually seen as unproblematic, provided
that certain conditions were adhered to, with each
treatment perceived as being effective in its own way.
These conditions reflected the instructions given by
health workers at the clinics, and included eating
properly, not taking medicines without prior testing such
as confirming malaria (slide or approved rapid diagnostic
tests) and taking appropriate doses for one’s weight. This
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HIV-positive patients’ concerns about taking drugs for
other infections without direction from doctors:
… they hesitate until they are advised by the doctor,
[the patient] can’t just fall sick and purchase drugs
from the shop, most of the time when they come for
the doctor’s consultation, that’s when they are told
‘you can use this’ or ‘you cannot use this’.
(IDI 08, hospital doctor).
Further, the stance on proper testing was emphasized
by those who believed mixing ARVs with other drugs
may cause some problems if proper medical tests and
weights described above, were not performed, such as
simply purchasing drugs from shops:
Negative effects to someone can occur if one
purchases drugs from the shop without performing
proper necessary tests. The drugs can affect
you because you do not know the dose you are
given from the shop is correct or not, yet also you
are on ARVs, so when taking them and they go
and badly interact and bring problems because
you have not done any tests and received
assurance from the doctor on how to use the
drugs. (R 08;FGD-C1; HIV- positive Female)
Realities of access to drugs
However, this view of the importance of attending a formal
health facility to be tested if experiencing malaria-like
symptoms before receiving appropriate treatment was
tempered by reports of confusion by participants who
had experienced malarial symptoms but subsequently
tested negative for the disease. A few people suggested this
might be linked to the nature of the ARVs they were
taking, which could cause similar symptoms to malaria: “...
sometimes the drugs’ condition can change… these drugs
sometimes bring tiredness” (R03; FGD A1; HIV-positive
female). This situation posed a challenge to participants
seeking relief for their symptoms, but who sought to
adhere to their perceived responsibility to take medicines
only after testing.
The view of what ‘should’ be done in the case of
malaria-like illness was also contrasted by discussions of
self-medication and seeking informal health services,
which were woven through accounts of treatment-seeking
among both HIV-positive and HIV-negative participants.
Such practices are the norm for malaria, and were
underpinned by a number of factors, including distance to
the health facility, lack of money for transport and fear of
stigma for HIV-positive patients. In all these situations,
poverty was reported to be a major cause compelling
people to self-medicate.Realities of pill burden
Taking ARVs concomitantly with anti-malarials was
spoken about by some in terms of the number of pills,
and the challenges faced in taking these. Most respon-
dents articulated the necessity of taking the numerous
pills in order to get better, provided that they had been
directed by a doctor. A few stated that without such in-
structions, taking many pills could be poisonous to the
body. This reflection of a biomedical discourse was also
apparent in descriptions by several participants of the
additional medicines they took for conditions over and
above HIV and malaria, for example TB or high blood
pressure, and how they were ‘used’ to taking numerous
drugs. However, there were also accounts of the efforts
involved in persevering with regimes, and descriptions
of the support needed by some patients – including
those who had not participated in the clinical study – to
achieve the ‘successful’ taking of all the necessary
medicines:
… at that moment I was taking nine tablets a day….it
reached a point I wanted to stop taking them… And if
I was alone until now I would not have felt better,
[but] I thank my children and my relatives, they
encouraged me. (R 02; FGD C2; HIV-positive female)
Health workers were vocal in expressing their concern
over pill burden to patients, arising from contact with
patients when prescribing medicines. They reported that
patients expressed fear when prescribed what they [pa-
tients] thought to be many pills, “Patients sometimes are
worried about the anti-malarial dose quantity especially
if they are also taking ARVs’ (IDI 08, Hospital-Doctor).
As a result, some health workers articulated their per-
ceived duty to provide assurance that the pills would not
be problematic. This challenge was particularly associ-
ated by health workers with patients who had recently
commenced ARVs and the problem was said to be com-
plex for patients taking their pills at home with health
workers fearing that they did not complete their doses.
Timing drugs
The notion of timing was also identified as important
for taking drugs concomitantly, with some participants
highlighting health workers’ role in stipulating the
schedule for drug-taking. As such, this echoed a formal
biomedical discourse in general, and ARV treatment
programme protocols more specifically, whereby medical
authority over drug-taking was respected by patients,
and appeared – for some participants at least – to be
accepted:
Facilitator (F): When you take [the drugs] at the same
time, what is the problem?
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R 06: Because you are following the doctor’s advice.”
(FGD A4; HIV-positive females).
Perceived medical authority also seemed to play a role
in some participants’ acceptance of the scheduled timing
of taking ARVs and anti-malarials, be it at the same
time or separately. Provided doctors had “arrange[d]
themselves when to take the drugs” (R 04; FGD A3;
HIV-positive male), these participants did not con-
sider there to be a problem with taking treatments
concomitantly.
However, a contrasting set of responses, identified
predominantly in the FGDs with people who had not
participated in the clinical study (sub-group C), conveyed
a sense of caution towards mixing drugs that was not
alleviated by the reassurances of health workers –
perhaps because of the non-trial setting. Participants
across the study sample perceived that the competing
strength, or ‘nguvu’, of medicines such as anti-malarials
and ARVs could lead to ‘friction’ or bad interactions.
Several participants described this in relation to per-
ceptions of their own health and strength, indicating
that possible negative effects of taking drugs at the
same time were linked to their individual condition,
in some cases suggesting they adjusted the schedules
of drugs to accommodate their perceived strength in
their own body:
F: What time is bad or good for taking drugs at once?
R 02: You can use malaria drugs and ARV and this
depends on your strength. For me, I can’t take [them]
at once, I have to have intervals [between them]. (FGD
C2, HIV-positive male).
It is important to separate the immediate
combination of the strength from ARVs and the other
drug. Because every drug has its own strength. I may
have to wait for a certain time, like one hour and a
half, the first drug taken would have already be
absorbed in its place inside the body. (R04; FGD-C1;
HIV-positive Female)
This account of drug strength and importance of
separating them also arose within a group of those who
participated in the trial. In this group two conflicting
perceptions were reported:
If I take ARVs at 6 am and I also have to take those of
malaria I extend like to wait two up to three hours. This
is because even the doctor also told me some drugs can
harm you if you take concomitantly so you have to
separate time. (R 09; FGD-A3- HIV positive Male)I take them at the same time because every drug does
its work at its section for example there was a time I
had to take 20 tablets and I take all because each
works differently so I think there is no problem with it.
(R 07; FGD-A3- HIV positive Male)
There were also several accounts of strategies adopted
by people to separate the timing of taking ARVs and
other drugs to limit the perceived anticipated negative
impact on their daily lives. Sometimes speaking about
medicines in general, rather than anti-malarials specifically,
several participants cited experiencing ‘body fatigue’ and
‘exhaustion’ as a result of taking drugs at the same time.
They described the importance of separating the timing of
drug-taking to ensure they were able to continue with their
work and other daily, household survival strategies:
… [if you do not separate the drugs] after taking the
drugs you [need to] find a place and rest… If you
haven’t finished your activities, it means you’ll hurt
yourself, working while the drugs are also working in
your body. (R 08; FGD C3; HIV-positive female).
Discussion
This study was conducted to begin to address the
paucity of literature on how people respond to HIV
and malaria co-infection, two major diseases affecting
sub-Saharan Africans, through specific focus on how
people make sense of concomitant treatments. Results
from this qualitative study show how people with HIV as
well as malaria have to straddle two paradigms of
treatment – the first as participants of a protocol of
care under the attention of dedicated specialists, and
the second as active agents seeking care for a familiar
disease for which treatment can be found with minimal
biomedical expertise required. Making sense of the
cross-over of these paradigms through experiences of
co-infection, participants of the trial who received
careful advice on taking medicines reiterated the
acquiescence to biomedical authority also seen in ARV
programmes. However, some, including those who had
been excluded from the trial, drew on broader experience
with self-medication of malaria to consider circumventing
this authority in treatment-seeking as well as tinker-
ing with timing of drugs. This potential for deviations
attended to both conceptual understandings and prac-
ticalities of concomitant medicine taking, and requires
further research.
In the context of the clinical trial where participants
were provided with comprehensive care and advice, as
well as small facilitators such as milk for swallowing
medicines, many appreciated and accepted the protocols of
concomitant medicine taking. This mirrored their accept-
ance of ARV regimens within treatment programmes, and
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contract’ of receiving ARVs and, in turn, in the general
acceptability of mixing drugs when regimens had been
‘authorized’ by doctors. In this setting in Tanzania, this may
reflect HIV-positive people’s sense of responsibility towards
adherence to treatment regimens, produced through
hierarchical relations between health workers and patients
[35] which have become institutionalised in HIV disease
control programmes.
This acceptance of the protocols of treatment, par-
ticularly for HIV, stood in contrast to discussions of
routine treatment of malaria, which involved more
personal experience of self-medication including choice of
drugs as well as timings, relating to experiences of the
strength of different drugs in one’s own body. While the
harmful effect of HIV co-infection on malaria incidence
and disease severity is now well documented in the
academic literature, including more frequent and more
severe malaria illness episodes [36], we found that people
living with HIV saw malaria as unavoidable, even ‘normal’.
This echoes the narratives of acceptance of misfortune
which can be found in numerous contexts where resources
are scarce and choices are limited [37].
When it came to managing concomitant medicines,
the realities of accessing treatment, the number of pills to
be taken and their perceived strength meant challenges
for many. While some reported adhering to protocols,
others spoke of adjusting the timing of taking different
drugs in order to accommodate perceptions of potential
‘friction’ between strong drugs, or to accommodate life in
general. Given the special sample of participants involved
in this study, associated with a clinical trial, these themes
require exploration in further research that follows the
everyday lives of people living with HIV as they navigate
the needs of concomitant medicines. Such research should
also investigate further the requirements of patients for
stepping across these different paradigms of different
disease control programmes. These early findings support
the call for health services to be oriented around patient
needs rather than the needs of specific disease control
programmes [38] and supports continued efforts towards
‘integrated care’.
This research, where acceptance of protocols was rooted
in the relationship between patients with health workers
providing a good service in a trial, and the authority
embedded in HIV treatment programmes, suggests that
promoting safe treatment practices of concomitant
medicines that are routinely taken as ‘normal’ such as
anti-malarials may be challenging. Public health interven-
tions have tended to focus on health promotion through
mass communication efforts, informing population groups
of lifestyle risks and preventive behaviours that will seal
their fates as ‘ill’ or ‘healthy’ [39]. The premise of such
interventions is that individuals can make choices, andthat the threat of specific forms of ill-health tomorrow will
outweigh other concerns and change behaviour today.
Much research now suggests that such interventions are
often unsuccessful because assumptions of individual
agency do not hold: political and economic circumstances
often constrain individual choices [40,41]. Furthermore,
social commitments are often given greater weight in daily
decisions than individual health-related activities [42]. In
Tanzania, malaria-related risks are played out against local
livelihood activities, such as farming, and particular social
engagements including funerals, which can shape sleeping
patterns and access to nets on a day-by-day basis [43]. In
line with findings among pregnant women in Malawi [44],
the lived realities of the study participants suggests that
for people living with HIV, the dangers of malaria are
known, and the authority of biomedical care is recognized,
but that test-before-treatment models of dealing with ill
health were impractical or irrelevant in the context of
their lives. The adherence to protocols reported by many
in this study therefore signals that other interventions are
required, and that bringing together care for patients
under one paradigm may be key to success.
Limitations
Although a range of perspectives were sought in this
qualitative study, the majority of participants included
may have different experiences and perceptions from
other people facing HIV and malaria co-infection, due to
their previous participation in the clinical study. Despite
being observational in design, offering the same treatments
as routine care in the surrounding health service, the
clinical study led its participants to conceptualize it as offer-
ing an enhanced ‘service’ [45]. The elements appearing to
comprising this perceived service included engaging with
the study team, materials and processes over an extended
period of time, as well as additional benefits such as
transport fare, which were interpreted as expressions
of individualized support from the study team. The
potential uniqueness of the sample of HIV-positive
people who had participated in the clinical study is a
limitation for generalizing the study findings more
broadly, particularly given the differences interpreted
between people who did and did not participate. However,
there is also potential to learn from the social and material
dynamics underpinning experiences of being in a clinical
study for informing routine care and how HIV-positive
people can be supported to align the challenges faced in
their daily socio-economic lives with the requirements of
treatment regimes [35,46].
Conclusions
Management of HIV and malaria concurrently often
requires individuals to cross the domains of different
disease programmes. In the context of a trial concerned
Mangesho et al. Malaria Journal 2014, 13:491 Page 8 of 9
http://www.malariajournal.com/content/13/1/491with both HIV and malaria, patients experienced the
support of clinicians in guiding and reassuring them
about when and how to take drugs concomitantly. This
presented an ‘integrated care’ scenario which appeared to
support patient confidence in concomitant medicine
taking following biomedical protocols. This points towards
the need to continue to strive for integrated care for
patients with HIV.
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